Curie: Healthcare in Focus

In this investigative episode, Mike dives deep into the unprecedented decision by Health Secretary Robert F. Kennedy Jr. to abruptly fire the entire CDC Advisory Committee on Immunization Practices (ACIP). Exploring the implications for public health, trust in vaccines, and healthcare policy, we examine the controversial backgrounds of new appointees and the urgent reactions from the medical commu...

We survey healthcare professionals constantly—on treatments, on tech, on trends. But how often is that research actually used to shape decisions? And what do clinicians really think about being surveyed in the first place? In this episode, we unpack the role of HCP market research in today’s healthcare economy. Why it’s done, how it’s evolving, and whether it still holds real value. Featuring insi...

In this episode of Curie, we dive into the early but extraordinary results from two CAR-T cell therapy trials that are rewriting what’s possible for glioblastoma—a brain cancer with a devastating prognosis. Andrew takes you through new data from Mass General and the University of Pennsylvania, where some patients have not just responded, but are alive and well nearly two years after treatment. Wit...

In this extended wrap-up from ASCO 2025, Mike breaks down four defining themes from the meeting: AI’s leap from buzzword to bedside, NIH funding threats that could shake innovation, China’s rising role in global oncology R&D, and five paradigm-shifting clinical trials with the potential to reshape patient care. Featuring insights from ASCO leadership, Google, and frontline HCPs from the ZoomRx...

Trump’s drug pricing executive order might sound bold—but what’s behind the rhetoric? In this episode of Curie, host Andrew sits down with Dr. David Introcaso, healthcare policy expert and host of The Healthcare Policy Podcast , to unpack the legal, economic, and political minefield that surrounds America’s $5 trillion healthcare system . From Medicare price negotiations to pharma's pushback, Dr....

In 2024, over twenty-seven thousand fewer Americans died of a drug overdose—a reversal so steep it stunned even veteran public health researchers. This episode unpacks the factors behind the historic decline: from naloxone’s expanded access to the work of drug-testing labs like UNC’s Opioid Data Lab. We also hear from voices on the front lines, including NPR’s Brian Mann and UNC’s Dr. Nabarun Dasg...

GLP-1s like Ozempic and Zepbound transformed obesity and diabetes treatment. But when shortages hit, compounding pharmacies and telehealth startups filled the gap with off-brand versions—cheap, accessible, and often unregulated. Now, that workaround is over. In this episode, we examine the FDA’s sweeping May 2025 ban on compounded GLP-1 drugs. What triggered it? What are the safety risks? And why...

Artificial intelligence is transforming how we detect disease—but what does that mean for the clinician-patient relationship? In this conversation, Dr. Andrew Wilner and Andrew Yukawa explore how diagnostic AI is reshaping everything from radiology to primary care. Together, they unpack the promise, the pitfalls, and the deeply human elements that machines still can’t replicate. From clinical judg...

In 2025, a six-month-old with a fatal genetic disorder became the first person to receive a CRISPR-based therapy tailored to their unique mutation. In this episode of Curie , host Mike unpacks how a team of researchers and clinicians raced against time to design, test, and deliver a one-time treatment that rewrote the rules of genomic medicine. From the science of base editing to the ethical and l...

A sweeping new executive order from Donald Trump promises to slash prescription drug prices by up to 80%. But behind the bold rhetoric lies a tangle of legal uncertainty, international trade implications, and real clinical consequences. In this episode of Curie, host Mike breaks down what’s actually in the order, why the pharmaceutical industry is pushing back, and what it all means for healthcare...

Ob/Gyns are walking away—and it's not just burnout. In this episode of Curie, we investigate the legal, financial, and political forces driving the crisis in women’s health. What happens when an entire specialty starts to disappear?

From ADHD to borderline personality disorder, mental health content is exploding on TikTok—and teens are listening. But is this wave of awareness helping patients, or muddying the waters for clinicians? In this episode of Curie, we explore how social media is changing the way symptoms are understood, identities are formed, and diagnoses are pursued. Featuring insights from clinicians and research...

In this post-conference episode, Mike breaks down five major stories from AACR 2025: KEYNOTE-689 trial changes the standard of care in head and neck cancer Zongertinib delivers HER2-targeted efficacy with fewer side effects in lung cancer CAR NK cells show durable remission in AML ctDNA testing in CRC detects recurrence 6+ months before imaging Werner helicase inhibitor shows first-in-class potent...

Once considered a short-term fix or semi-retirement gig, locum tenens has become a deliberate career choice for tens of thousands of physicians across the U.S. We discuss: What people still misunderstand about locum tenens How variety and exposure shape clinical growth Why more doctors are walking away from traditional career tracks The traits that make someone a great fit for locums—and the trait...

A plan to link together massive datasets about autistic Americans has triggered fierce debate. Critics fear it’s a surveillance effort in disguise. Federal agencies say it’s about research. And the autistic community? They're raising serious concerns about privacy, ethics, and unintended consequences. In today’s episode of Curie, Mike unpacks what’s happening inside the Department of Health and Hu...

Seventy years ago, Jonas Salk changed history with the first successful polio vaccine—an innovation that reshaped public health and saved millions of lives. But what does his legacy mean in a world now grappling with vaccine skepticism, science politicization, and resurging preventable diseases? In this episode of Curie, we reflect on Salk’s radical generosity, the ethics of scientific discovery,...

In this Curie episode, Matt previews what’s coming at AACR 2025, happening April 25–30 in Chicago. Get ready for a data-packed week with practice-changing trials like KEYNOTE-689 and Beamion LUNG-1, along with fresh momentum in AI-powered oncology, cancer interception, and new modalities like peptide drug conjugates and RNA-targeting agents. From early detection to trial equity, this preview outli...

A cancer vaccine? It’s not science fiction anymore. In this episode of Curie , host Andrew unpacks a groundbreaking personalized vaccine trial led by Dr. Vinod Balachandran at Memorial Sloan Kettering. By training the immune system to recognize mutations unique to each patient’s tumor, this approach is rewriting the rules of cancer care. We explore how mRNA, long known for its role in COVID vaccin...

In this special Curie episode, Matt covers the biggest clinical updates from the 2025 American Academy of Neurology Annual Meeting . Learn how CNM-Au8 is showing real signs of remyelination in MS , why AXS-05 may be the next approved treatment for Alzheimer’s agitation , and how Vyepti is delivering long-term migraine relief . We also spotlight Mi-Helper, a noninvasive cooling device for migraines...

Measles is back—and it’s not just a public health story, it’s a political one . In this episode of Curie , we explore how the virus is spreading through undervaccinated communities and what the data tells us about the role of vaccine hesitancy. But we also look at what happens when the newly appointed HHS Secretary—Robert F. Kennedy Jr.—has a long record of casting doubt on vaccines. From CDC guid...

Is a diagnosis always the right answer? In this episode of Curie , we explore the growing debate around overdiagnosis, featuring neurologist Suzanne O’Sullivan’s provocative insights . As diagnostic rates for autism, ADHD, anxiety, and depression soar, we ask: Are we better at recognizing real struggles—or have we redrawn the line between normal and abnormal? This episode challenges assumptions, s...

In this episode, Matt dives into the largest restructuring in the history of the U.S. Department of Health and Human Services. With 10,000 staff laid off across the FDA, CDC, NIH, and beyond, what happens to the public health infrastructure clinicians rely on? Learn what’s changing, who it affects, and what HCPs should be watching closely.

Love what you hear? Download the Curie app from the App Store today . Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. Rising drug prices. Critical shortages. Vanishing innovation. In this in-depth episode of Curie , Matt investigates how proposed pharmaceutical tariffs could upend...

Love what you hear? Download the Curie app from the App Store today . Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. As political pressures mount, key players in healthcare are shifting away from ‘equity’ toward ‘optimization.’ But what does this really mean for funding, research...

Love what you hear? Download the Curie app from the App Store today . Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. Prior authorizations, endless paperwork, and frustrating denials—healthcare professionals know this battle all too well. But how does this bureaucratic nightmare t...